This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment

An aim of the study was to investigate the efficacy and safety of noojerone (memantine) in patients with cognitive impairment comorbid to brain ischemia, stages II-III. The main group (30 patients, aged 64-86 years) was treated with noojerone in addition to standard therapy according to dosage scheme during 6 months. The control group (15 patients, […]

Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer’s disease

Treatment with cholinesterase inhibitors can cause tolerability-related problems in many patients. To facilitate the titration process, rivastigmine, a novel form of the drug (solution), has been elaborated. An objective of the study was to compare efficacy, safety and tolerability of rivastigmine (exelon) used in conventional capsules and/or solution and to assess adherence to this drug […]

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia

This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson’s disease complicated by dementia, as compared with a control group of patients not treated with memantine. Patients of the experimental group (32 subjects) received memantine (20 mg/day), while […]